Unraveling the Stereochemical Complexity of Phosphorothioate-Modified Oligonucleotides Using Analytical Technologies
Nucleic Acid Therapeutics · 01.08.2026 · 36 (4) · 202-215
DOI: 10.1177/21593337261452594 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acid Therapeutics, online erschienen am 27.05.2026. Verfasst von Akanksha Manghrani und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Bioscience and Biotechnology Research, National Institute of Standards and Technology, University of Maryland, Rockville, Maryland, USA. Hauptthemen laut MEDLINE: Phosphorothioate Oligonucleotides, Oligonucleotides, Antisense. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: Center for Drug Evaluation and Research.
Abstract (Originalsprache)
Oligonucleotide therapeutics are emerging as a promising modality for targeting disease-associated RNAs. Phosphorothioate (PS)-containing oligonucleotides have gained prominence due to their enhanced stability and pharmacodynamic properties. However, current manufacturing practices afford a mixture of R p and S p stereoisomers, and this distribution has been linked to changes in product efficacy. Understanding the sensitivity of analytical methods to changes in this quality attribute has therefore become critically important. Here, we used a suite of analytical techniques—ultraviolet (UV) thermal denaturation, circular dichroism (CD), and nuclear magnetic resonance (NMR) spectroscopy—to evaluate the PS diastereomer distribution using Tegsedi, a Food and Drug Administration-approved PS-containing antisense oligonucleotide, and with other synthetic inotersen samples having varied PS diastereomer distributions. While UV and CD techniques showed limited sensitivity, NMR excelled in detecting small changes in the PS diastereomer distribution. The univariate metric of 31 P integration was shown to be insufficient for this quality metric evaluation; application of principal component analysis to both 1D 31 P and 2D 1 H, 13 C spectra revealed distinct PS changes that arose from the different activators used during manufacturing. This comprehensive evaluation highlights the necessity of advanced analytical techniques in ensuring the quality and consistency of PS-containing oligonucleotide therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Bioscience and Biotechnology Research, National Institute of Standards and Technology, University of Maryland, Rockville, Maryland, USA.
- Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, Maryland, USA.
ORCID-Profile: Akanksha Manghrani, Maharshi C Patel
Förderung
- Center for Drug Evaluation and Research
Zitieren
APA
Manghrani, A., Patel, M. C., Delaglio, F., Ali, M., Szramowski, M., Fletcher, S., Jones, J. W., & Brinson, R. G. (2026). Unraveling the Stereochemical Complexity of Phosphorothioate-Modified Oligonucleotides Using Analytical Technologies. Nucleic Acid Therapeutics, 36(4), 202-215. https://doi.org/10.1177/21593337261452594
Vancouver
Manghrani A, Patel MC, Delaglio F, Ali M, Szramowski M, Fletcher S, et al. Unraveling the Stereochemical Complexity of Phosphorothioate-Modified Oligonucleotides Using Analytical Technologies. Nucleic Acid Therapeutics. 2026;36(4):202-215. doi:10.1177/21593337261452594
BibTeX
@article{Manghrani2026,
author = {Manghrani, Akanksha and Patel, Maharshi C and Delaglio, Frank and Ali, Mohsin and Szramowski, Mirandia and Fletcher, Steven and Jones, Jace W and Brinson, Robert G},
title = {Unraveling the Stereochemical Complexity of Phosphorothioate-Modified Oligonucleotides Using Analytical Technologies},
journal = {Nucleic Acid Therapeutics},
year = {2026},
volume = {36},
number = {4},
pages = {202--215},
doi = {10.1177/21593337261452594}
}
EUVIMED